Friday, 8. June 2018
Next Milestone reached for HALIX
Agreement on real property signed between Leiden University and HALIX.
HALIX has reached an important milestone in realising a brand-new 6.700 m² GMP facility with development and production clean rooms. By signing an agreement with the Leiden University, HALIX obtained real property at the Leiden Bio Science Park.
HALIX will soon start the construction activities. The new facility will be designed for state of the art GMP manufacturing projects, and is expected to be fully operational in 2019.
“As our business is growing, we require additional production and laboratory capacity to continue serving our customers. We are happy to expand here, in the centre of the Leiden Bio Science Park, as the development and opportunities of the Leiden Bio Science Park are an added value to our business, and offer a perfect environment for our activities.” says Harry Flore, CEO of HALIX.
HALIX is a contract development & manufacturing organization (CDMO) and licensed for clinical and commercial GMP contract manufacturing of biopharmaceuticals. We provide services to biopharmaceutical partners, enabling them to harvest on their research activities, and to enter and supply their markets with the most efficient use of resources. Our focus is GMP manufacturing of biologics, by manufacturing drug substance through mammalian cell culturing, and by performing aseptic fill and finish and lyophilization services. Within the next years we are extending the scope of services for therapeutic proteins and viral vaccines.
The Leiden Bio Science Park is the largest science cluster in the Netherlands and brings together Leiden University, Leiden University Medical Center (LUMC), and approximately 150 companies in close proximity. There is a lot of energy and expertise moving around between companies in the Bio Science Park. Being part of that is a great benefit for HALIX.
Founded in 2012 HALIX, a corporate venture and spin-off of HAL Allergy, is a contract development and manufacturing organization (CDMO), based in Leiden, the Netherlands. The company is licensed for the contract manufacturing of clinical and commercial medicines according to GMP standards. HALIX leverages advanced biopharmaceutical technologies and provides the full portfolio of pharmaceutical documentation of GMP production processes, as well as production of units which are required for clinical approval. HALIX, as an end-to-end service provider, will serve its customers the full range from the first development steps to start of commercial production after successful registration of products. More information is available on: www.halix.nl
HALIX and HAL Allergy Group belong to the family owned Droege Group AG.
About Droege Group
Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in "special situations". With the guiding principle "execution - following the rules of art", the group is a pioneer in execution-oriented corporate development. Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries. More information is available on www.droege-group.com
Monique Lutgens - Manager Corporate Communications
Tel. + 31 (0)88 1959010